Trevi Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Net Income	-29.07	-29.15	-33.94	-32.76	-26.75	Upgrade
Depreciation & Amortization	0.12	0.04	0.05	0.05	0.04	Upgrade
Share-Based Compensation	2.25	2.33	2.54	2.42	1.13	Upgrade
Other Operating Activities	-5.02	-1.39	2.4	1.29	1.79	Upgrade
Operating Cash Flow	-31.71	-28.18	-28.95	-29	-23.09	Upgrade
Capital Expenditures	-0.14	-0.16	0	-0.03	-0.01	Upgrade
Change in Investments	59.57	-107.21	0	0	0	Upgrade
Investing Cash Flow	59.43	-107.37	0	-0.03	-0.01	Upgrade
Share Issuance / Repurchase	1.85	117.39	21.23	3.18	65.14	Upgrade
Debt Issued / Paid	-9.5	-5.85	-0.07	13.92	-0.68	Upgrade
Other Financing Activities	-0.26	-0.23	-0.38	-0.38	8.75	Upgrade
Financing Cash Flow	-7.91	111.31	20.78	16.72	73.21	Upgrade
Net Cash Flow	19.81	-24.24	-8.17	-12.31	50.11	Upgrade
Free Cash Flow	-31.85	-28.33	-28.95	-29.03	-23.1	Upgrade
Free Cash Flow Per Share	-0.32	-0.44	-1.27	-1.61	-1.97	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).